Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Republicans Turn Their Backs On Califf

Executive Summary

A visual comparison of Robert Califf’s US FDA Commissioner confirmation votes in 2016 and 2022.

You may also be interested in...



Mifepristone Access Imperiled By Supreme Court’s Draft Decision Overturning Abortion Rights

Clinicians in states that ban abortion could face criminal prosecution for providing mifepristone. Access to medical abortion ‘is not a panacea’ if the court overrules Roe v. Wade as people using the drug face risks from aggressive prosecutors, ACLU attorney says.

Califf Clears First Senate Hurdle, But FDA Abortion Pill Decision May Complicate Final Confirmation

Republican opposition to Califf over the agency’s recent move to relax its Mifeprex restrictions is ominous since in order be confirmed as FDA commissioner he’ll need enough GOP votes to make up for Democratic opposition over his opioid track record and connections to the drug industry.

Withdraw Califf FDA Nomination, Sanders Demands

Citing close ties to the biopharmaceutical industry and a lack of commitment to lowering drug prices, Sen. Bernie Sanders (I-VT) on Jan. 26 demanded President Barack Obama withdraw his nomination of Robert Califf to lead the FDA.

Topics

Latest News
UsernamePublicRestriction

Register

PS145708

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel